Investigational RA Drug
Dr. Roy M. Fleischmann discusses Phase 2 results concerning an oral drug (CP-690550) used as monotherapy in the treatment of rheumatoid arthritis. Mitchel Zoler of the Global Medical News Network (GMNN) reports from the annual European Congress of Rheumatology in Copenhagen.
This entry was posted on Monday, February 22nd, 2010 at 2:34 am and is filed under ADDICTION NEWS. You can follow any responses to this entry through the RSS 2.0 feed.
Both comments and pings are currently closed.